InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M
Rhea-AI Summary
InMode (NASDAQ: INMD), a leading medical technology provider, has announced preliminary Q2 2025 financial expectations and revised its full-year guidance. The company expects Q2 2025 revenue between $95.4-$95.5 million with a non-GAAP gross margin of 79-80%.
Due to market weakness and U.S. economic uncertainty, InMode has decreased its full-year 2025 revenue guidance to $365-375 million, down from the previous guidance of $395-405 million. The company will discuss detailed Q2 2025 results in a conference call scheduled for July 30, 2025.
Positive
- Expected Q2 2025 non-GAAP gross margin of 79-80% shows strong profitability
- Maintaining high-margin business model despite market challenges
Negative
- Reduced full-year 2025 revenue guidance by approximately $30 million
- Market weakness and economic uncertainty affecting business performance
- Expected Q2 revenue indicates potential growth challenges
News Market Reaction 1 Alert
On the day this news was published, INMD declined 0.33%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time
YOKNEAM,
InMode is currently finalizing its financial results for the second quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may arise between now and the time such financial results are finalized.
Due to continued market weakness and persistent uncertainty surrounding the
- Revenue for the second quarter of 2025 to be in the range of
$95.4 million $95.5 million - Non-GAAP1 gross margin for the second quarter of 2025 to be in the range of
79% to80% - Full year 2025 revenue to be in the range of
$365 million $375 million $395 million $405 million
1Please refer to "Use of Non-GAAP Financial Measure" below for important information about non-GAAP financial measures. Non- GAAP results exclude share-based compensation.
InMode will host a conference call to discuss the second quarter 2025 financial results on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time. Speakers will include Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer and Dr. Michael Kreindel, Chief Technology Officer.
The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10201337/ff895a1432. Callers will receive a unique dial-in upon registration, which enables immediate access on the day of the call. Participants may pre-register at any time, including up to and after the call start time.
For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.
Israel Toll-Free: 1-80-921-2373
International: 1-412-317-5736 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=LXTC7h0D
At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time
The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from July 30, 2025, at 12:00 p.m. Eastern Time to August 13, 2025, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:
Replay
Replay TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 4085483
A replay will also be available for 90 days on InMode's website at: https://inmodemd.com/investors/events-presentations/.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 04, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.
Use of Non-GAAP Financial Measures
In addition to InMode's operating results presented in accordance with GAAP, this release includes non-GAAP gross margin. Because this measure is used in InMode's internal analysis of financial and operating performance, management believes that it provides greater transparency to investors of management's view of InMode's economic performance. Management also believes the presentation of this measure, when analyzed in conjunction with InMode's GAAP operating results, allows investors to evaluate and compare the performance of InMode to that of its peers, although InMode's presentation of its non-GAAP measure may not be comparable to other similarly titled measures of other companies more effectively.
Company Contact: Yair Malca Chief Financial Officer Email: Yair.Malca@inmodemd.com | Investor Relations Contact: Miri Segal MS-IR LLC Email: ir@inmodemd.com |
Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg
View original content:SOURCE InMode Ltd.
FAQ
What is InMode's (INMD) revised revenue guidance for 2025?
What are InMode's (INMD) expected Q2 2025 financial results?
Why did InMode (INMD) lower its 2025 revenue guidance?
When will InMode (INMD) report its Q2 2025 earnings?
What is InMode's (INMD) expected gross margin for Q2 2025?
